Harmony Biosciences Holdings, Inc. (HRMY)

In the past six months, Harmony Biosciences reported its Fourth Quarter 2025 financial results, posting earnings per share (EPS) of $0.57, which missed analysts' expectations. The company received FDA approval for WAKIX for the treatment of cataplexy in pediatric narcolepsy. Harmony Biosciences announced strong preliminary, unaudited net product revenue for Q4 and full year 2025, with WAKIX on track to achieve over $1 billion in revenue in 2026. The company strengthened its executive team with new appointments and additions to its board. Harmony Biosciences participated in several investor conferences and announced positive results from a pivotal bioequivalence study for pitolisant's gastro-resistant formulation. As of April 10, 2026, the stock price had declined in 6 of the last 10 days, resulting in a total change of 5.28% during that period.

While narcolepsy can exhibit seasonal variations in symptoms, there is no direct evidence to suggest significant seasonality in the demand for Harmony Biosciences' products or services. The narcolepsy treatment market itself is experiencing consistent growth, driven by increasing awareness and diagnosis rates. Harmony Biosciences has demonstrated strong and consistent revenue growth, suggesting that any potential seasonality in the underlying condition's symptoms may not directly translate into significant sales seasonality.

Harmony Biosciences Holdings, Inc. is a biopharmaceutical company focused on developing therapies for rare neurological and endocrine diseases. Their flagship product is WAKIX (pitolisant), an FDA-approved treatment for excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. The company is also exploring pitolisant for other sleep disorders and cognitive conditions and has several other drug candidates in its pipeline.

Harmony Biosciences is headquartered in Plymouth Meeting, Pennsylvania, and has a commercial infrastructure across the United States. The company is also exploring strategic partnerships and licensing arrangements to expand into international markets.

Harmony Biosciences maintains a reputation focused on patient-centric innovation and addressing unmet medical needs in rare disease communities. The company's mission emphasizes positively impacting the lives of underserved patients. In the past year, Harmony Biosciences has been involved in a television broadcast about pediatric narcolepsy, which it sponsored, highlighting its commitment to patient education and support. News releases generally reflect positive developments such as product approvals, strong financial performance, and advancements in its pipeline.

Harmony Biosciences Holdings, Inc. has significant institutional ownership, with 86.23% of its stock held by institutions. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Fmr Llc, American Century Companies Inc, Dimensional Fund Advisors Lp, State Street Corp, Lsv Asset Management, Arrowstreet Capital, Limited Partnership, Geode Capital Management, Llc, and Renaissance Technologies Llc. Insiders hold 23.60% of the company's stock.